COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry

Shane Hanon; Guy Brusselle; Maud Deschampheleire; Renaud Louis; Alain Michils; Rudi Peché; Charles Pilette; Peter Rummens; Daniel Schuermans; Hélène Simonis; Olivier Vandenplas; Florence Schleich

doi:10.1183/13993003.02857-2020

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry

Eur Respir J. 2020 Oct 22;56(6):2002857. doi: 10.1183/13993003.02857-2020. Online ahead of print.

Authors

Affiliations

¹ Respiratory Division, University Hospital UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
² Department of Respiratory Medicine, Ghent University Hospital, Gent, Belgium.
³ Department of Respiratory Medicine, CHR Citadelle, Liege, Belgium.
⁴ Department of Respiratory Medicine, University Hospital of Liege, Liege, Belgium.
⁵ Chest Department, Erasme University Hospital, Université Libre de Bruxelles (ULB), Bruxelles, Belgium.
⁶ Department of Respiratory Medicine, ISPPC, CHU Charleroi, Charleroi, Belgium.
⁷ Department of Respiratory Medicine, Cliniques Universitaires St-Luc and institute of Experimental and Clinical Research, Université Catholique de Louvain (UCL), Bruxelles, Belgium.
⁸ Department of Respiratory Medicine, University Hospital Saint-Pierre, Université Libre de Bruxelles, Bruxelles, Belgium.
⁹ Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Cliniques Universitaires de Mont-Godinne, Université Catholique de Louvain, Yvoir, Belgium.

Abstract

In a cohort of severe asthma patients, a small number of COVID-19 cases was found; none resulted in death or a very severe disease course. Use of biologics for severe allergic or severe eosinophilic asthma was not associated with a higher risk of COVID-19. https://bit.ly/3ndZmyD

Publication types

Letter